Serum Hyaluronate As a Non-invasive Marker of Hepatic Fibrosis and Inflammation in HBeAg-negative Chronic Hepatitis B

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2005 Oct 14

PMID 16221307

Citations 26

Authors

Ghodrat Montazeri

Arezoo Estakhri

Mehdi Mohamadnejad

Negin Nouri

Farhad Montazeri

Ashraf Mohammadkani

Mohammad Hossain Derakhshan

Farhad Zamani

Shahram Samiee

Reza Malekzadeh

Affiliations

Soon will be listed here.

Abstract

Background: HBV infection is a serious global heath problem. It is crucial to monitor this disease more closely with a non-invasive marker in clinical trials. We aimed to evaluate the predictive value of serum hyaluronate for the presence of extensive liver fibrosis and inflammation.

Methods: 28 healthy volunteers and 65 patients with HBeAg negative chronic hepatitis B were enrolled. Liver biopsies scored according to Ishak system. Association of serum hyaloronate with liver fibrosis and inflammation were assessed, and cut off points for serum hyaluronate levels were identified by receiver operating characteristics (ROC) curves and their values for prediction of fibrosis and inflammation were assessed.

Results: In patients with CHB serum hyaluronate had the most significant correlation and predictive values for the liver fibrosis and inflammation comparing to the other variables. At the cut off point of 126.4 ngm/ml it could discriminate extensive fibrosis from milder ones with sensitivity of 90.9% and specificity of 98.1%. With the same value it could discriminate extensive inflammation from their milder counterparts with sensitivity of 63.6% and specificity of 92.6%.

Conclusion: Serum hyaluronate was the best predictor of extensive liver fibrosis and inflammation and it could discriminate subgroups of patients with chronic hepatitis B. It could be used as a non-invasive test to monitor these patients more closely with developing anti viral agents in clinical trials.

Citing Articles

Biomarkers for Assessment of Human Immunodeficiency Virus and its Co-Infection with Hepatitis B and Hepatitis C Viruses: A Comprehensive Review.

Abdi M, Ahmadi A, Mokarizadeh A Iran J Pathol. 2023; 18(3):230-243.

PMID: 37942194 PMC: 10628369. DOI: 10.30699/IJP.2023.1972384.3009.

Clinical importance of laboratory biomarkers in liver fibrosis.

Aleknaviciute-Valiene G, Banys V Biochem Med (Zagreb). 2022; 32(3):030501.

PMID: 36277426 PMC: 9562801. DOI: 10.11613/BM.2022.030501.

Musculoskeletal Biomarkers Response to Exercise in Older Adults.

Abreu E, Vance A, Cheng A, Brotto M Front Aging. 2022; 3:867137.

PMID: 35821851 PMC: 9261344. DOI: 10.3389/fragi.2022.867137.

Potential role of noninvasive biomarkers during liver fibrosis.

Kaur N, Goyal G, Garg R, Tapasvi C, Chawla S, Kaur R World J Hepatol. 2022; 13(12):1919-1935.

PMID: 35069998 PMC: 8727215. DOI: 10.4254/wjh.v13.i12.1919.

A Generic Nomogram Predicting the Stage of Liver Fibrosis Based on Serum Biochemical Indicators Among Chronic Hepatitis B Patients.

Xu X, Wang W, Zhang Q, Cai W, Wu M, Qin T Front Med (Lausanne). 2021; 8:669800.

PMID: 34616750 PMC: 8488358. DOI: 10.3389/fmed.2021.669800.

References

Quinn P, Johnston D . Detection of chronic liver disease: costs and benefits. Gastroenterologist. 1997; 5(1):58-77. View

Nyberg A, Engstrom-Laurent A, Loof L . Serum hyaluronate in primary biliary cirrhosis--a biochemical marker for progressive liver damage. Hepatology. 1988; 8(1):142-6. DOI: 10.1002/hep.1840080127. View

Maharaj B, Maharaj R, Leary W, Cooppan R, Naran A, Pirie D . Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986; 1(8480):523-5. DOI: 10.1016/s0140-6736(86)90883-4. View

Fraser J, Laurent T, Engstrom-Laurent A, Laurent U . Elimination of hyaluronic acid from the blood stream in the human. Clin Exp Pharmacol Physiol. 1984; 11(1):17-25. DOI: 10.1111/j.1440-1681.1984.tb00235.x. View

Ueno T, Inuzuka S, Torimura T, Tamaki S, Koh H, Kin M . Serum hyaluronate reflects hepatic sinusoidal capillarization. Gastroenterology. 1993; 105(2):475-81. DOI: 10.1016/0016-5085(93)90722-o. View

ISHAK K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F . Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6):696-9. DOI: 10.1016/0168-8278(95)80226-6. View

Smedsrod B, Pertoft H, Eriksson S, Fraser J, Laurent T . Studies in vitro on the uptake and degradation of sodium hyaluronate in rat liver endothelial cells. Biochem J. 1984; 223(3):617-26. PMC: 1144344. DOI: 10.1042/bj2230617. View

Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T . Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 357(9262):1069-75. DOI: 10.1016/S0140-6736(00)04258-6. View

Croquet V, Vuillemin E, Ternisien C, Pilette C, Oberti F, Gallois Y . Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol. 2002; 14(10):1133-41. DOI: 10.1097/00042737-200210000-00015. View

10.

Gressner A, Schafer S . Comparison of sulphated glycosaminoglycan and hyaluronate synthesis and secretion in cultured hepatocytes, fat storing cells, and Kupffer cells. J Clin Chem Clin Biochem. 1989; 27(3):141-9. DOI: 10.1515/cclm.1989.27.3.141. View

11.

Dienstag J, Goldin R, Heathcote E, Hann H, Woessner M, Stephenson S . Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003; 124(1):105-17. DOI: 10.1053/gast.2003.50013. View

12.

Phillips M, Preedy V, Hughes R . Assessment of prognosis in alcoholic liver disease: can serum hyaluronate replace liver biopsy?. Eur J Gastroenterol Hepatol. 2003; 15(9):941-4. DOI: 10.1097/00042737-200309000-00001. View

13.

Wai C, Greenson J, Fontana R, Kalbfleisch J, Marrero J, Conjeevaram H . A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38(2):518-26. DOI: 10.1053/jhep.2003.50346. View

14.

Chopra S, Griffin P . Laboratory tests and diagnostic procedures in evaluation of liver disease. Am J Med. 1985; 79(2):221-30. DOI: 10.1016/0002-9343(85)90013-0. View

15.

Piccinino F, Sagnelli E, Pasquale G, Giusti G . Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986; 2(2):165-73. DOI: 10.1016/s0168-8278(86)80075-7. View

16.

Gibson P, Fraser J, Brown T, Finch C, Jones P, Colman J . Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. Hepatology. 1992; 15(6):1054-9. DOI: 10.1002/hep.1840150614. View

17.

Cadranel J, Mathurin P . Prothrombin index decrease: a useful and reliable marker of extensive fibrosis?. Eur J Gastroenterol Hepatol. 2002; 14(10):1057-9. DOI: 10.1097/00042737-200210000-00004. View

18.

Ding H, Chen Y, Feng X, Liu D, Wu A, Zhang L . [Correlation between liver fibrosis stage and serum liver fibrosis markers in patients with chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi. 2001; 9(2):78-80. View

19.

Cadranel J, Rufat P, Degos F . Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000; 32(3):477-81. DOI: 10.1053/jhep.2000.16602. View

20.

Truppe W, Basner R, von Figura K, Kresse H . Uptake of hyaluronate by cultured cells. Biochem Biophys Res Commun. 1977; 78(2):713-9. DOI: 10.1016/0006-291x(77)90237-6. View